# Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

> **NCT02661282** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 65 (actual)

## Conditions studied

- Cytomegalovirus Positive
- Glioblastoma
- Gliosarcoma
- Malignant Glioma
- Recurrent Brain Neoplasm
- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temozolomide
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02661282
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661282, "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02661282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*